Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Osborn, Gary ^b   Escofet, Xavier ^c   Da Silva, Anthony ^a  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Arteriovenous shunt, surgical *adverse effects; methods ; Chemotherapy, adjuvant; Kidney failure, chronic *therapy ; Platelet aggregation inhibitors *therapeutic use ; Randomized controlled trials as topic; Renal dialysis methods

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FISH OIL; PLACEBO; SULFINPYRAZONE; TICLOPIDINE; WARFARIN;

ARTERIOVENOUS FISTULA; ARTERY INJURY; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC DISEASE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMATOMA; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIVER DISEASE; LOW DRUG DOSE; OUTCOME ASSESSMENT; POLITEF IMPLANT; RESPIRATORY TRACT HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; REVIEW; SINGLE DRUG DOSE; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; VASCULAR PATENCY; VASCULITIS; VEIN GRAFT;

EID: 55049122198     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002786.pub2     Document Type: Review

References (34)

1. Andrassy 1974 {published data only} Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: Results of a prospective double blind study. Klinische Wochenschrift 1974;52(7):348-9.
2. Crowther 2002 {published data only} Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, et al.Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. Journal of the American Society of Nephrology 2002;13 (9):2331-7.
3. Fiskerstrand 1984 {published data only} Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for haemodialysis. Artificial Organs 1985;9(1): 61-3.
4. Grontoft 1985 {published data only} Grontoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology and Nephrology 1985;19(1):55-7.
5. Grontoft 1998 {published data only} Grontoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in A-V fistula surgery in uremia. Fistual Study Group. Scandinavian Journal of Urology and Nephrology 1998;32(4):276-83.
6. Harter 1979 {published data only} Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al.Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. New England Journal of Medicine 1979;301(11): 577-9.
7. Michie 1977 {published data only} Michie DD, Wombolt DG. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research, Clinical and Experimental 1977;22(1):196-204.
8. Schmitz 2002 {published data only} Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: doubleblind, randomized, prospective trial. Journal of the American Society of Nephrology 2002;13:184-90.
9. Sreedhara 1994 {published data only} Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized double blind study. Kidney International 1994;45(5):1477-83.
10. Trimarche 2006 {published data only} Trimarche H, Young P, Forrester M, Schropp J, Pereyra H, Fexias E. Clopidogrel diminishes hemodiaysis access graft thrombosis. Nephron. Clinical Practice 2006;102:128- 32.
11. Albert 1978 {published data only} Albert FW, Schmidt U, Harzer R. Postoperative thromboprophylaxis for Cimino-fistulae with sulfinpyrazone in comparison to acetylsalicylic acid. Krankenhausarzt 1978;51:712-8.
12. Dulude 2001 {published data only} Dulude H, Kaplan M, Odland M, Marbury T, Hoggard JG, Ploth D, et al.Escalating single doses of CJC-1004, a locally acting antithrombotic agent in hemodialysis patients with vascular access occlusion. Journal of the American Society of Nephrology 2001;12:287A.
13. Janicki 2003 {published data only} Janicki K, Bojarska SA, Pietura R, Janicka L. Preventive effects of ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients. Annales Universitatis Mariae Curie Sklodowska Sectio D: Medicina 2003;58:215-8.
14. Kaegi 1975 {published data only} Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 1975;52(3):497-9.
15. Kaufman 2003 {published data only} Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology 2003;14(9):2313-21.
16. Krasinski 2004 {published data only} Krasinski Z, Dzieciuchowicz L, Kulesza J, Pietrzak I, Gabriel M, Krasinka B, Oszkinis G. Influence of long-term therapy with low molecular weight heparin on patency of arterio-venous fistula for hemodialysis. ERA - EDTA ELI Congress Abstracts. 2004:360.
17. Radmilovic 1998 {published data only} Radmilovic A, Boric Z, Naumovic T, Stamenkovic M, Musikic P. Shunt thrombosis prevention in hemodialysis patients - A doubleblind, randomized study: pentoxifylline vs placebo. Angiology 1998; 38(7):499-506.
18. Dember 2005 {published data only} Dember L, Kaufman J, Beck G, Dixon B, Gassman J, Greene T, et al.Dialysis Access Consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis. Journal of the American Society of Nephrology 2002;13:229A.
19. * Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al.Design of the dialysis access consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials 2005; 2(5):413-22.
20. Dixon 2005 {published data only} Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, et al.Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clinical Trials 2005;2(5):400-12.
21. Fuster 2001 {published data only} Fuster V, Charlton P, Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Human Gene Therapy 2001;12(16):2025-7.
22. Irish 2007 {published data only} * Irish A. A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin and fish oil in the prevention of early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis - FAVOURED (Fish oil and Aspirin in Vascular acccess OUtcomes in REnal Disease). Cochrane Renal Group Prospective Trials Register [http://www.cochrane renal.org./dbsearch.php.] 2007.
23. Irish A. Fish oil and aspirin in vascular access outcomes in renal disease. Australasian Kidney Trials Network [http: //www.uq.edu.au./aktn./index. html.] 2007.
24. Lok 2007 {published data only} Anon. Fish oil Inhibition of Stenosis in Haemodialysis grafts study. http://www.controlled-trials.com/ ISRCTN15838383/15838383 (accessed 18 May 2008) 2007.
25. * Lok CE, Allon M, Donnelly S, Dorval M, Hemmelgarn B, Moist L, et al.Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials 2007;4(4):357-67.
26. Mileti 1995 {published data only} Mileti M, De Petri G, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology 1995;8(2):167-72.
27. Churchill 1992 Churchill DN, Taylor DW, Cook RJ, Laplante P, Barre P, Cartier P, et al.Canadian Hemodialysis Morbidity Study. American Journal of Kidney Disease 1992;19(3):214-34.
28. DOQI 1997 Anonymous. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation - Dialysis Outcomes Quality Initiative. American Journal of Kidney Diseases 1997;30 Suppl 3:150-91.
29. Jadad 1996 Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al.Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1): 1-12.
30. Kanterman 1995 Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic localisation of venous stenosis and results of angioplasty. Radiology 1995;195(1):135-9.
31. Kaplan 1958 Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.
32. Metha 1991 Metha S. Statistical summary of clinical results of vascular access procedures for haemodialysis. In: Sommer BG, Henry ML editor(s). Vascular Access for Hemodialysis-II (Chapter 11). W L Gore, 1991: 145-57.
33. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
34. Cochrane 2003 Da Silva AF, Escofet X, Rutherford PA. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD002786]